Differentiating JAK Inhibitors From Other Therapies in AD

EP: 1.Intro to Janus Kinase (JAK) Inhibitors for Treatment of Atopic Dermatitis (AD)

EP: 2.Targeting the JAK-STAT Pathway in AD

Now Viewing

EP: 3.Differentiating JAK Inhibitors From Other Therapies in AD

EP: 4.Indications and Efficacy of JAK Inhibitors for AD

EP: 5.Safety of JAK Inhibitors Approved for AD Treatment

EP: 6.Boxed Warnings for JAK Inhibitors in AD

EP: 7.Contraindications for Use of JAK Inhibitors in AD

EP: 8.Treatment Selection of JAK Inhibitors for the Management of AD

EP: 9.Utilizing JAK Inhibitors in Clinical Practice

EP: 10.Access to JAK Inhibitors in AD

EP: 11.Clinical Pearls for the Treatment of AD

This is a video synopsis/summary of a panel discussion involving Christopher Bunick, MD, PhD; Peter Lio, MD; Lisa Swanson, MD, PhD; and Alexandra Golant, MD.

Dr Peter Lio, MD, discusses the distinguishing features of JAK (Janus kinase) inhibitors in the context of treating atopic dermatitis. He emphasizes 2 significant aspects that set JAK inhibitors apart from other therapies. Firstly, in the realm of systemic treatments, where there were limited approved options until recently, biologic agents targeting specific cytokines required subcutaneous injections and had a slower onset. In contrast, JAK inhibitors, administered orally, exhibit a remarkably rapid response within hours to days, offering a level of disease control that surpasses previous treatments.

The focus on itch as a crucial aspect of atopic dermatitis treatment is highlighted. Dr Lio refers to a study published in the British Journal of Dermatology, revealing the substantial improvement in quality of life for patients achieving an itch level of zero or 1. The conversation emphasizes the need to address itch comprehensively, not just focusing on skin signs. Achieving itch scores of zero or 1 is identified as a crucial goal for optimal patient outcomes.

The discussion underscores the transformative impact of JAK inhibitors in the field, offering a new tool that informs a "treat to target" approach. The ability to aim for zero itch, coupled with the rapid efficacy of JAK inhibitors, has raised the standards for treating atopic dermatitis. The conversation among the experts reflects a consensus that JAK inhibitors have elevated the efficacy bar, not only in terms of skin clearance but also in addressing itch and improving overall quality of life for patients. The introduction of these inhibitors has empowered clinicians to ask different questions and strive for a higher standard of care, ultimately benefiting patients with atopic dermatitis.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.